Our team of experts are passionate about developing new capsids, promoters, and GOIs that can be used to treat a wide range of diseases.

We have developed a large-scale and low-cost AAV production solution platform that is making gene therapy more accessible to patients around the world.

By leveraging collaborations with academic institutions and industry leaders, we are working to create a future whereby gene therapy is an integral component of healthcare systems.

Look no further! Our team has achieved the remarkable development of three clinical pipelines passing IND in 2022-2023, reducing timelines by 50%, which is significantly faster than industry benchmarks.

The rapid development times is due to our implementation of efficient preclinical models and in silico analysis.

Trust us to deliver results, end-to-end AAV pipeline solutions, that exceed your expectations and join the list of satisfied clients.

With our comprehensive pharmaceutical research and manufacturing process and a skilled R&D team, we are the perfect solution for your requirements.

With our expansive GMP production facility covering over 8,000 square meters, we are fully equipped to expertly handle even the most challenging projects.

Don't compromise; opt for our unmatched quality and expertise in gene therapy development and manufacturing.

Real&Best is dedicated to working closely with institutions, organizations, companies, and individuals to advance treatments for patients and their families affected by genetic and age-related diseases.

In our partnerships, we bring together our foremost experts and the pioneering spirit that defines our company.

We deeply appreciate the expertise our partners bring to the table, and we are dedicated to cultivating enduring relationships.

When we unite our efforts, we unleash the full potential of our shared goals.

rAAV gene therapy represents a groundbreaking advancement in medicine, offering new hope for individuals affected by rare genetic diseases. With an estimated 7,000 medical conditions stemming from gene disorders lacking targeted treatments, the potential impact of this therapy is immense. Unlike traditional approaches, rAAV gene therapy directly delivers therapeutic genes to cells, offering the possibility of curing diseases with a single treatment. Notably, eight drugs have already been approved globally to treat rare diseases, including Hemophilia and DMD. Furthermore, this therapy shows promise in addressing diseases with poor therapeutic outcomes, such as neurological conditions like AD, PD, and ALS, along with aging-related diseases like sarcopenia and osteoarthritis.

Real&Best has achieved significant milestones since its establishment in 2018. Over the past six years, the company has successfully conducted a number clinical studies and obtained approval for three INDs. Our clinical pipelines focus on addressing genetic diseases such as Hemophilia A, Hemophilia B, Fabry, and the aging-related disease sarcopenia. With a 10,100 m2 facility, including 1,500 m2 dedicated to research and 8,600 m2 for GMP production and quality control, we have the infrastructure to drive innovation and progress. Our team of 130 experienced personnel brings a wealth of bioproduction experience, expertise in rAAV gene therapy development and manufacturing, and a commitment to ensuring the success of drug development through dedication, attention to detail, and innovative thinking.